Autolus Therapeutics (NASDAQ:AUTL) Shares Up 3.9%

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price rose 3.9% during mid-day trading on Tuesday . The company traded as high as $4.00 and last traded at $3.99. Approximately 381,037 shares were traded during mid-day trading, a decline of 75% from the average daily volume of 1,512,714 shares. The stock had previously closed at $3.84.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a research report on Monday, June 17th. William Blair reiterated an “outperform” rating on shares of Autolus Therapeutics in a research report on Monday, June 3rd. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $8.70.

Autolus Therapeutics Price Performance

The firm has a 50 day moving average price of $4.00 and a 200-day moving average price of $4.77. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -3.30 and a beta of 2.11.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Perceptive Advisors LLC acquired a new position in Autolus Therapeutics in the fourth quarter valued at approximately $11,793,000. Price T Rowe Associates Inc. MD boosted its position in shares of Autolus Therapeutics by 82.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after purchasing an additional 2,487,778 shares during the last quarter. BNP Paribas Financial Markets boosted its position in shares of Autolus Therapeutics by 2,603.8% in the 1st quarter. BNP Paribas Financial Markets now owns 115,399 shares of the company’s stock worth $736,000 after purchasing an additional 111,131 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in shares of Autolus Therapeutics during the fourth quarter worth $768,000. Finally, SG Americas Securities LLC bought a new stake in Autolus Therapeutics in the first quarter valued at about $127,000. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.